These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30148769)

  • 21. Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases.
    Amagai R; Muto Y; Kato H; Matsushita S; Maekawa T; Fukushima S; Yoshino K; Uchi H; Fujisawa Y; Yamamoto Y; Ohuchi K; Kambayashi Y; Fujimura T
    Melanoma Res; 2021 Dec; 31(6):575-578. PubMed ID: 34524222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple Therapy Improves Colorectal Cancer Response.
    Cancer Discov; 2016 Dec; 6(12):OF6. PubMed ID: 27770002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
    Hennemann A; Puzenat E; Decreuse M; Vuillier F; Nardin C; Aubin F
    Melanoma Res; 2024 Jun; 34(3):280-282. PubMed ID: 38602773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
    Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib.
    Shimada S; Fukushima S; Niimori D; Miyashita A; Setoyama H; Sasaki Y; Ihn H
    J Dermatol; 2018 Jun; 45(6):e157-e158. PubMed ID: 29315749
    [No Abstract]   [Full Text] [Related]  

  • 27. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
    Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
    Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanoma in 2017: Moving treatments earlier to move further forwards.
    Davies MA; Flaherty KT
    Nat Rev Clin Oncol; 2018 Feb; 15(2):75-76. PubMed ID: 29182162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.
    Mistry HB; Orrell D; Eftimie R
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):325-332. PubMed ID: 29222604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus Trametinib.
    Geçgel A; Ön S; Çiftçi Y; Özkan O; Açar FP; Karaca B
    Balkan Med J; 2024 Jul; 41(4):312-313. PubMed ID: 38572561
    [No Abstract]   [Full Text] [Related]  

  • 32. Erythema Nodosum-Like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib.
    Martínez-Rodríguez I; García-Castaño A; Quirce R; Jiménez-Bonilla J; Banzo I
    Clin Nucl Med; 2017 Jan; 42(1):44-46. PubMed ID: 27775948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy.
    Harrison SR; Tew A; Steven N; Fisher BA
    Rheumatology (Oxford); 2018 Aug; 57(8):1497-1499. PubMed ID: 29617934
    [No Abstract]   [Full Text] [Related]  

  • 34. Discrepancy in responses to dabrafenib plus trametinib combination therapy in intracranial and extracranial metastases in melanoma patients.
    Kobayashi T; Matsumoto S; Shimizu K; Miyake M; Maeda S; Hamaguchi Y; Matsushita T
    J Dermatol; 2021 Feb; 48(2):e82-e83. PubMed ID: 33161591
    [No Abstract]   [Full Text] [Related]  

  • 35. Successful use of crushed formulation of dabrafenib and trametinib in a pediatric glioneural tumor.
    Mamdouhi T; Vagrecha A; Johnson AA; Levy CF; Atlas M; Krystal JI
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29187. PubMed ID: 34185373
    [No Abstract]   [Full Text] [Related]  

  • 36. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GSK drug combination approved for advanced melanoma.
    Inman S
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors.
    Mizukami Y; Kanemaru H; Nakamura K; Hashigo S; Kajihara I; Miyashita A; Aoi J; Fukushima S; Honda Y; Ihn H
    J Dermatol; 2020 Apr; 47(4):e126-e127. PubMed ID: 31872454
    [No Abstract]   [Full Text] [Related]  

  • 39. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
    Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete response for 36 months after BRAF and MEK inhibitor therapy for locally advanced gallbladder melanoma.
    Hakim S; Orosey M; Edhi A; Amin M; Cappell MS
    Minerva Gastroenterol Dietol; 2019 Sep; 65(3):243-246. PubMed ID: 31115206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.